canin
parvoviru
type
first
identifi
describ
unit
state
australia
close
relat
felin
panleukopenia
viru
fpv
viru
name
unrel
viru
canin
parvoviru
type
caus
neonat
death
puppi
caus
sever
diarrhea
vomit
predilect
young
puppi
result
high
mortal
due
myocard
enter
spread
rapidli
becom
global
distribut
two
year
first
identifi
demonstr
contagi
pathogen
popul
canid
furthermor
evolv
genet
variant
continu
identifi
complet
replac
global
canid
new
variant
cpv
type
viru
underw
antigen
drift
new
variant
cpv
type
observ
subsequ
anoth
novel
cpv
variant
detect
sever
countri
mutat
variant
map
abund
structur
protein
revers
highli
infecti
lead
high
morbid
mortal
dog
current
vaccin
best
measur
prophylaxi
cpv
infect
nevertheless
regardless
rel
high
cost
concern
effect
exist
vaccin
concern
efficaci
exist
clinic
therapi
addit
symptomat
treatment
includ
antiserum
interferon
treatment
therefor
drug
therapi
infect
altern
strategi
warrant
attent
lithium
salt
signific
therapeut
agent
use
treat
sever
noninfecti
diseas
antivir
effect
lithium
chlorid
licl
dna
rna
virus
investig
licl
inhibit
replic
dna
viru
herp
simplex
inhibit
replic
rna
virus
encephalomyocard
viru
influenza
viru
recent
sever
report
demonstr
antivir
effect
licl
dna
virus
herp
simplex
viru
pseudorabi
herpesviru
porcin
parvoviru
late
antivir
effect
licl
rna
virus
bronchiti
coronaviru
transmiss
gastroenter
viru
type
ii
porcin
reproduct
respiratori
syndrom
viru
also
demonstr
report
indic
licl
might
potenti
antivir
drug
virus
studi
investig
whether
licl
could
inhibit
replic
vitro
explor
antivir
mechan
licl
newest
strain
use
studi
maintain
laboratori
viru
isol
sick
dog
guangdong
provinc
china
sequenc
pcr
method
found
contain
substitut
felin
kidney
cell
obtain
american
type
cultur
collect
atcc
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
usa
contain
fetal
bovin
serum
fb
hyclon
logan
ut
penicillinstreptomycin
gibco
ca
licl
sigma
st
loui
mo
usa
dissolv
dmem
steril
passag
filter
cytotox
assay
perform
accord
manufactur
instruct
donjindo
japan
assay
cell
cultur
plate
serumfre
dmem
prevent
cell
replic
hour
allow
cell
adher
plate
cell
wash
three
time
pb
incub
licl
seri
concentr
mm
dmem
fb
five
wellsdilut
h
control
five
well
mock
treat
wash
pb
dmem
solut
ad
well
plate
incub
h
optic
densiti
od
valu
measur
use
micropl
reader
biorad
usa
wavelength
nm
rel
cell
viabil
calcul
mean
drug
mean
control
cytotox
concentr
calcul
use
graphpad
prism
graphpad
softwar
san
diego
usa
cell
cell
cultur
plate
nontox
concentr
mm
licl
mix
cpv
ad
cell
incub
h
control
cell
infect
dose
cpv
treat
licl
subsequ
antivir
efficaci
evalu
analysi
viral
rna
level
protein
express
level
cpe
addit
interferon
express
level
also
determin
cell
cell
cultur
overnight
plate
fb
dmem
nontox
concentr
mm
licl
mix
cpv
inocul
cell
incub
h
maxim
bind
control
cell
infect
dose
cpv
licl
treatment
remov
drug
unbound
virus
wash
cold
dmem
cell
lysat
subject
three
freezethaw
cycl
prepar
measur
viral
load
cell
cell
cultur
overnight
plate
fb
dmem
infect
cpv
h
remov
unbound
virus
cold
dmem
cell
incub
nontox
concentr
mm
licl
h
control
cell
infect
dose
cpv
licl
treatment
wash
cold
dmem
cell
cultur
fb
dmem
h
cell
lysat
subject
three
freezethaw
cycl
prepar
measur
viral
load
cell
cell
cultur
overnight
plate
fb
dmem
infect
cpv
h
allow
viru
entri
wash
cold
dmem
cell
treat
nontox
concentr
mm
licl
cultur
fb
dmem
h
control
cell
infect
dose
cpv
licl
treatment
subsequ
cell
lysat
subject
three
freezethaw
cycl
prepar
measur
viral
load
total
dna
extract
use
ra
pure
viral
dna
kit
magen
china
accord
instruct
manufactur
pcr
primer
gene
cpv
list
tabl
total
mrna
extract
trizol
reagent
invitrogen
carlsbad
ca
usa
convert
cdna
use
oligo
primer
pcr
primer
list
tabl
realtim
quantit
pcr
perform
use
realtim
pcr
system
appli
biosystem
usa
green
pcr
master
mix
kit
appli
biosystem
usa
accord
instruct
manufactur
method
normal
gapdh
use
calcul
rel
mrna
express
level
cell
cultur
plate
inocul
cell
lysat
serial
dilut
tenfold
dmem
five
replic
cultiv
h
cell
observ
cytopath
effect
calcul
method
reed
muench
cell
wash
pb
fix
paraformaldehyd
min
permeabil
triton
min
wash
three
time
pb
cell
incub
mous
anticpv
antibodi
abcam
britain
h
subsequ
fitcconjug
goat
antimous
igg
zhongshan
china
use
secondari
antibodi
refer
protein
nuclear
stain
done
dapi
accord
instruct
manufactur
invitrogen
carlsbad
ca
usa
final
fluoresc
observ
leica
b
microscop
leica
wetzlar
germani
experi
perform
triplic
result
report
mean
standard
deviat
sd
signific
differ
experiment
group
determin
use
unpair
ttest
oneway
anova
use
prism
softwar
graphpad
softwar
pvalu
select
indic
signific
cytotox
concentr
licl
mm
fig
licl
caus
seriou
cellular
toxic
high
concentr
eg
mm
concentr
mm
cytostat
concentr
fig
effect
cell
morpholog
compar
mocktreat
cell
data
shown
therefor
mm
use
nontox
concentr
rang
licl
antivir
test
investig
antivir
activ
licl
cpv
licl
ad
seri
concentr
mm
prior
cpv
infect
realtim
qpcr
assay
mean
rel
viral
dna
level
mocktreat
cell
cell
treat
mm
licl
mocktreat
cell
set
respect
fig
viru
titrat
tissu
cultur
infect
dose
viral
titer
mocktreat
cell
treat
mm
licl
respect
fig
indirect
immunofluoresc
assay
ifa
mocktreat
cell
produc
stronger
fluoresc
signal
hour
infect
cpv
fluoresc
signal
declin
treatment
mm
licl
fig
examin
microscopi
show
cpv
infect
result
detach
mani
cell
mm
treatment
prevent
cell
detach
fig
result
indic
treatment
cell
licl
inhibit
cpv
infect
reduc
cytopath
effect
dosedepend
manner
rel
mrna
level
also
determin
level
cell
cpv
licl
cpvlicl
significantli
differ
compar
mocktreat
cell
fig
viral
attach
entri
replic
assay
perform
determin
step
viral
life
cycl
affect
licl
treatment
cell
signific
differ
rel
level
viral
gene
dna
viral
titer
observ
drugtreat
mocktreat
cell
indic
licl
effect
cpv
attach
replic
cell
fig
b
viral
entri
test
rel
level
viral
gene
dna
mocktreat
cell
treat
mm
licl
respect
fig
viral
titer
mocktreat
cell
treat
mm
licl
respect
fig
result
indic
cpv
entri
cell
inhibit
dosedepend
manner
treatment
licl
purpos
studi
determin
whether
licl
could
use
potenti
cur
agent
first
licl
concentr
mm
determin
signific
toxic
cell
signific
effect
cell
morpholog
second
licl
treatment
viral
dna
viral
protein
level
decreas
cell
morpholog
improv
result
indic
licl
inhibit
cpv
infect
cell
howev
ifn
express
affect
licl
treatment
indic
innat
immun
system
impact
licl
thu
potenti
antivir
effect
licl
explor
viral
life
cycl
cpv
infect
includ
attach
cell
entri
cell
replic
nucleu
stage
viral
life
cycl
evalu
licl
treatment
studi
cpv
attach
specif
receptor
cell
initi
step
viral
life
cycl
attach
step
signific
viru
host
tropism
found
viral
attach
affect
licl
treatment
cpv
replic
nucleu
requir
certain
cellular
factor
express
phase
cell
cycl
also
found
viral
replic
affect
licl
treatment
cpv
enter
cell
via
endocyt
rout
involv
microtubuledepend
deliveri
cpv
endosom
process
mediat
rapid
remov
viru
via
clathrinco
vesicl
result
indic
cpv
entri
cell
inhibit
dosedepend
manner
licl
indic
clathrinco
vesicl
might
affect
licl
treatment
conclus
cpv
infect
inhibit
dosedepend
manner
licl
treatment
cell
antivir
effect
licl
step
cpv
entri
cell
inhibit
might
involv
clathrinco
vesicl
research
requir
determin
cpv
entri
cell
affect
licl
whether
licl
antivir
effect
vivo
